25E-NBOMe


25E-NBOMe, also known as 2C-E-NBOMe or NBOMe-2C-E, is a derivative of the phenethylamine 2C-E. It acts in a similar manner to related compounds such as 25I-NBOMe, which are potent agonists at the 5-HT2A receptor. 25E-NBOMe has been sold as a drug and produces similar effects in humans to related compounds such as 25I-NBOMe and 25C-NBOMe.

Use and effects

The dose range of 25E-NBOMe has been given as 0.1 to 1.0mg sublingually, with a typical dose estimate of 0.3mg.

Toxicity and harm potential

Neurotoxic and cardiotoxic actions

Emergency treatment

Interactions

Pharmacology

Pharmacodynamics

25E-NBOMe acts as an agonist of the serotonin 5-HT2 receptors. In accordance with its psychedelic effects in humans, it produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents.
25E-NBOMe has shown reinforcing effects in rodents. This included conditioned place preference and self-administration. The reinforcing effects of 25E-NBOMe were mediated by increased dopaminergic signaling in the nucleus accumbens. Blockade of the dopamine D1 receptor could attenuate the CPP induced by 25E-NBOMe.

History

25E-NBOMe was first described in the scientific literature by 2012.

Society and culture

Legal status

Canada

25E-NBOMe is a controlled substance in Canada under phenethylamine blanket-ban language.

Sweden

Sweden's public health agency classified 25E-NBOMe as a narcotic substance, on January 18, 2019.

United Kingdom

United States

25E-NBOMe is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.